Please provide your email address to receive an email when new articles are posted on . NAPLES, Fla. — After implantation of the Ex-PRESS microshunt in eyes with uveitic glaucoma, the success rate was ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SAN FRANCISCO — A glaucoma shunt and trabeculectomy ...

Dr. Rhee answers the question: 'When Are Shunts Used For Glaucoma?' Aug. 24, 2009— -- Question: What are shunts, when are they used to treat glaucoma, and what are the risks/benefits? Answer: ...

The results of a new study show donor corneas not suitable for transplants may serve as a more effective alternative to traditional tissue for patients needing tissue to cover a glaucoma shunt, ...

Glaucoma is the second most common cause of blindness in the United States and worldwide. [1,2] It is a progressive optic neuropathy characterized by nerve atrophy and loss of retinal ganglion cells.

The multi‐site VITA trial, a prospective pilot study designed to assess the safety and effectiveness of Avisi Technologies' investigational VisiPlate® device, enrolled and treated 15 subjects (mean ...

To analyze 12- and 24-month visual acuity, intraocular pressure, and complications associated with combined pars plana vitrectomy (PPV) and glaucoma tube shunt placement in eyes with glaucoma. A ...

The MarketWatch News Department was not involved in the creation of this content.-- The first VisiPlate surgery in the US for the SAPPHIRE Trial was performed by Dr. Snyder of Sac ...

For example, currently, CMS considers ICD-9-CM series 365.10-365.15, open-angle glaucoma as medically necessary to perform Category III code 0192T. Operative documentation must support all conditions ...

Multiple randomized trials have evaluated the efficacy of aqueous shunts for lowering IOP in patients who have failed maximal medical management. None of the trials directly compare the use of aqueous ...

REDWOOD CITY, Calif., April 2, 2025 /PRNewswire/ -- Avisi Technologies, a clinical-stage ophthalmic device company, today announced encouraging six‐month interim results from the VITA trial evaluating ...